Inversago Pharma Receives $7 Million in Series A FinancingProceeds will support the development of new generations of cannabinoid-1 (CB1) receptor inverse agonists for the treatment of several metabolic diseases including Prader-Willi Syndrome (PWS) and type 1 diabetes (T1D). MONTREAL, July 25, 2018-- Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases.